Cellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenström Macroglobulinemia

• Cellectar BioSciences plans to submit an FDA accelerated approval application for iopofosine I 131 in Waldenström macroglobulinemia in the first half of 2027.
• Potential US accelerated approval is targeted for the second half of 2027.
• The Phase 3 confirmatory trial targets approximately 200 patients, with first enrollment projected for the first quarter of 2027.
• Phase 2b data showed an 83.6% overall response rate; median response duration reached 17.8 months.
• Estimated total Phase 3 trial cost is $42 million, with progression-free survival data expected 24–30 months following first patient enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.